{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:46:00Z","timestamp":1793321160159,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.neuropharm.2012.06.039","type":"journal-article","created":{"date-parts":[[2012,7,2]],"date-time":"2012-07-02T04:49:17Z","timestamp":1341204557000},"page":"371-379","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity"],"prefix":"10.1016","volume":"64","author":[{"given":"Emilio","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Citraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Davoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gallelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Donato Di Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.06.039_bib1","unstructured":"Abilify [package insert]. New York, NY: Bristol-Meyers Squibb Company\/Otsuka America Pharmaceutical Inc., 2004."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib2","series-title":"The WAG\/Rij Rat Model of Absence Epilepsy: the Nijmegen\u2013Moscow Research","first-page":"99","article-title":"Characterization of learning and memory in WAG\/Rij rats prone to absence epilepsy","author":"Bazyan","year":"2000"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2004.12.001","article-title":"Distribution of D1-like and D2-like dopamine receptors in the brain of genetic epileptic WAG\/Rij rats","volume":"63","author":"Birioukova","year":"2005","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0165-0327(11)70003-9","article-title":"Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder","volume":"128","author":"Blier","year":"2011","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00213-009-1583-7","article-title":"Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice","volume":"206","author":"Bourin","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib6","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.neuropharm.2005.05.013","article-title":"Effects of novel antipsychotics with mixed D(2) antagonist\/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat","volume":"49","author":"Bruins Slot","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib7","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S1734-1140(11)70605-3","article-title":"Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats","volume":"63","author":"Burda","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1528-1167.2010.02520.x","article-title":"Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy","volume":"51","author":"Canevini","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00213-010-2065-7","article-title":"Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex","volume":"214","author":"Carli","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1023\/A:1026179013847","article-title":"Genetic animal models for absence epilepsy: a review of the WAG\/Rij strain of rats","volume":"33","author":"Coenen","year":"2003","journal-title":"Behav. Genet."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2741\/s153","article-title":"Cognition, dopamine and bioactive lipids in schizophrenia","volume":"3","author":"Condray","year":"2011","journal-title":"Front. Biosci. (Schol. Ed.)"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0091-3057(94)90472-3","article-title":"Ethopharmacological analysis of rat behavior on the elevated plus-maze","volume":"49","author":"Cruz","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0306-4522(00)00266-9","article-title":"Dopamine in the striatum modulates seizures in a genetic model of absence epilepsy in the rat","volume":"100","author":"Deransart","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2008.06.100","article-title":"Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms","volume":"592","author":"Egashira","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0031-9384(98)00129-2","article-title":"Reduced exploratory activity of audiogenic seizures susceptible Wistar rats","volume":"64","author":"Garcia-Cairasco","year":"1998","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib17","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/schbul\/sbm074","article-title":"Molecular targets for treating cognitive dysfunction in schizophrenia","volume":"33","author":"Gray","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0091-3057(96)00402-9","article-title":"Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test","volume":"57","author":"Griebel","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2003.07.009","article-title":"Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia","volume":"66","author":"Harvey","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.neubiorev.2009.11.019","article-title":"Neural mechanisms supporting acquired phasic dopamine responses in learning: an integrative synthesis","volume":"34","author":"Hazy","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4161\/cam.3.1.7401","article-title":"Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models","volume":"3","author":"He","year":"2009","journal-title":"Cell. Adh. Migr."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1358\/dot.2003.39.7.799445","article-title":"Antipsychotic medication and seizures: a review","volume":"39","author":"Hedges","year":"2003","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.yebeh.2003.08.020","article-title":"Common pathogenic mechanisms between depression and epilepsy: an experimental perspective","volume":"3","author":"Jobe","year":"2003","journal-title":"Epilepsy. Behav."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.expneurol.2007.09.026","article-title":"Elevated anxiety and depressive-like behavior in a rat model of genetic generalized epilepsy suggesting common causation","volume":"209","author":"Jones","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib25","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/S0924-977X(02)80421-7","article-title":"Aripiprazole is a potent, partial agonist at cloned human D2L and native 5-HT1A receptors","volume":"13","author":"Jordan","year":"2002","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1254\/jphs.08201SC","article-title":"Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test","volume":"108","author":"Kamei","year":"2008","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib28","first-page":"52","article-title":"The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders","volume":"64","author":"Kane","year":"2003","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2005.07.038","article-title":"One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia","volume":"81","author":"Keefe","year":"2006","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.neuropharm.2012.06.039_bib30","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/ajp.2007.164.7.1061","article-title":"Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"Keefe","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pnpbp.2009.08.025","article-title":"Serious generalized tonic-clonic seizures induced by aripiprazole","volume":"34","author":"Li","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib32","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.neuropharm.2010.01.008","article-title":"Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum","volume":"58","author":"Lovinger","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib33","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/j.1528-1167.2011.03325.x","article-title":"Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments","volume":"52","author":"Luoni","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/070674370505000318","article-title":"Aripiprazole-induced seizure [letter]","volume":"50","author":"Malik","year":"2005","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0006-8993(01)02705-6","article-title":"Electrophysiological and pharmacological characteristics of two types of spike-wave discharges in WAG\/Rij rats","volume":"911","author":"Midzianovskaia","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jneumeth.2005.12.014","article-title":"Measuring clusters of spontaneous spike-wave discharges in absence epileptic rats","volume":"154","author":"Midzyanovskaya","year":"2006","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib37","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0893-133X(01)00368-2","article-title":"Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)-6H-[1]benzothieno[2, 3-b][1, 5] benzodiazepine maleate)","volume":"26","author":"Morimoto","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib38","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00213-008-1240-6","article-title":"Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors","volume":"202","author":"Nagai","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib39","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nn.2647","article-title":"Animal models of neuropsychiatric disorders","volume":"13","author":"Nestler","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00023210-200822050-00002","article-title":"Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence","volume":"22","author":"Pae","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/11538980-000000000-00000","article-title":"Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data","volume":"25","author":"Pae","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.euroneuro.2005.12.002","article-title":"Dopaminergic-based pharmacotherapies for depression","volume":"16","author":"Papakostas","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib43","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib44","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib45","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1001\/archpsyc.61.6.556","article-title":"Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression","volume":"61","author":"Rosa-Neto","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib46","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.neuropharm.2003.11.028","article-title":"Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy","volume":"46","author":"Russo","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib47","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/j.1528-1167.2009.02400.x","article-title":"Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy","volume":"51","author":"Russo","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib48","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1528-1167.2011.03112.x","article-title":"Effects of early long-term treatment with antiepileptic drugs, on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model","volume":"52","author":"Russo","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib49","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbr.2011.07.030","article-title":"Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity","volume":"225","author":"Russo","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib50","first-page":"302","article-title":"Antipsychotics as antidepressants: what is the mechanism?","volume":"23","author":"Sagud","year":"2011","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib51","first-page":"462","article-title":"A\u00a0new experimental model of depression: WAG\/Rij rats genetically predisposed to absence epilepsy","volume":"374","author":"Sarkisova","year":"2000","journal-title":"Dokl. Biol. Sci."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbr.2005.07.024","article-title":"Behavioral characteristics of WAG\/Rij rats susceptible and non-susceptible to audiogenic seizures","volume":"166","author":"Sarkisova","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib53","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.pnpbp.2010.11.010","article-title":"The WAG\/Rij strain: a genetic animal model of absence epilepsy with comorbidity of depression [corrected]","volume":"35","author":"Sarkisova","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib54","first-page":"733","article-title":"Depression-like changes in behavior and c-fos gene expression in dopaminergic brain structures in WAG\/Rij rats","volume":"52","author":"Sarkisova","year":"2002","journal-title":"Zh. Vyssh. Nerv. Deiat. Im. I P Pavlova"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0166-4328(03)00090-1","article-title":"Depressive-like behavioral alterations and c-fos expression in the dopaminergic brain regions in WAG\/Rij rats with genetic absence epilepsy","volume":"144","author":"Sarkisova","year":"2003","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib56","first-page":"91","article-title":"Dopamine-dependent character of depressive-like behavior in WAG\/Rij rats with genetic absence epilepsy","volume":"57","author":"Sarkisova","year":"2007","journal-title":"Zh. Vissh. Nervn. Dejat."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11055-008-0017-z","article-title":"Dopamine-dependent nature of depression-like behavior in WAG\/Rij rats with genetic absence epilepsy","volume":"38","author":"Sarkisova","year":"2008","journal-title":"Neurosci. Behav. Physiol."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib58","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1528-1167.2009.02260.x","article-title":"Spike-wave discharges are necessary for the expression of behavioral depression-like symptoms","volume":"51","author":"Sarkisova","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib59","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.neuint.2009.06.003","article-title":"Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats","volume":"55","author":"Segnitz","year":"2009","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib60","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00213-011-2262-z","article-title":"Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain","volume":"217","author":"Segnitz","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib61","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1254\/jphs.11201FP","article-title":"Effect of aripiprazole on anxiety associated with ethanol physical dependence and on ethanol-induced place preference","volume":"118","author":"Shibasaki","year":"2012","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.eplepsyres.2009.01.016","article-title":"Electroencephalographic precursors of spike\u2013wave discharges in a genetic rat model of absence epilepsy: power spectrum and coherence EEG analyses","volume":"84","author":"Sitnikova","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbr.2008.03.018","article-title":"Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors","volume":"191","author":"Snigdha","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib65","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1017\/S1092852900016837","article-title":"Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry","volume":"13","author":"Stein","year":"2008","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib66","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1124\/jpet.106.106047","article-title":"Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism","volume":"320","author":"Terry","year":"2007","journal-title":"JPET"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/jcp.0b013e3181618eb4","article-title":"Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies","volume":"28","author":"Thase","year":"2008","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib68","doi-asserted-by":"crossref","first-page":"995","DOI":"10.4088\/JCP.v67n0619b","article-title":"Aripiprazole-associated seizure","volume":"67","author":"Tsai","year":"2006","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib69","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2011.03044.x","article-title":"A\u00a0prospective case control study of psychiatric disorders in adults with epilepsy and intellectual disability","volume":"52","author":"Turky","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib70","series-title":"New Research on Epilepsy and Behavior","first-page":"211","article-title":"Stress vulnerability and depressive symptoms in genetic absence epileptic rats","author":"van Luijtelaar","year":"2007"},{"key":"10.1016\/j.neuropharm.2012.06.039_bib71","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.neulet.2011.02.034","article-title":"The prevention of behavioral consequences of idiopathic generalized epilepsy: evidence from rodent models","volume":"497","author":"van Luijtelaar","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2012.06.039_bib72","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bcp.2005.11.007","article-title":"Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms","volume":"71","author":"Zhang","year":"2006","journal-title":"Biochem. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T06:27:25Z","timestamp":1542868045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812002973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":72,"alternative-id":["S0028390812002973"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.06.039","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}